Allogene Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Allogene Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Allogene Therapeutics Inc
Rating: 1.35308325
Author: Trendlyne DVM scores

about

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...

1.79 0.00 (0.00%)

59.87% Fall from 52W High

4.9M

XNAS Volume

XNAS 17 Jul, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

9.8 / 100

Technically Neutral

44.3 / 100

1Yr Price target upside is 317%

12 analysts

Allogene Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Allogene Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...

59.87% Fall from 52W High

SWOT Analysis

Allogene Therapeutics Inc Live Price Chart

Allogene Therapeutics Inc Live Price Chart